Table 1.
The formulations and pH values of anti-VEGF agents
| Drug | Concentration (osmolarity) | Dose in the vitreous (4 ml)/dose in 0.002 ml | Formulation | Measured pH | 95% CI |
|---|---|---|---|---|---|
| Ranibizumab (Lucentis) | 10 mg/ml (289 mOsm) | 0.5 mg/0.02 mg | 10 mM histidine-HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20 | 5.32 | 5.0–5.63 |
| Bevacizumab (Avastin) | 25 mg/ml (182 mOsm) | 1.25 mg/0.05 mg | 42 mM NaH2PO4·H2O, 8.45 mM Na2HPO4, 6% α,α-trehalose dihydrate, 0.04% polysorbate 20 | 5.91 | 5.63–6.19 |
| Aflibercept (Eylea) | 40 mg/ml (286 mOsm) | 2 mg/0.08 mg | 10 mM Na3PO4, 40 mM NaCl, 5% sucrose, 0.03% polysorbate 20 | 6.05 | 5.78–6.31 |
| Ziv-aflibercept (Zaltrap) | 25 mg/ml (1000 mOsm) | 1.25 mg/0.05 mg | 100 mM NaCl, 5 mM Na citrate, 5 mM Na3PO4, 20% sucrose, 0.1% polysorbate 20 | 6.1 | 6.05–6.15 |
| Rituximab (Rituxan) | 10 mg/ml | 1 mg/0.02 mg | 154 mM NaCl, 25 mM Na citrate·2 H2O, 0.07% polysorbate 80 | 6.29 | 5.97–6.61 |